Breast Cancers

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

National Clinical Trial ID:: NCT07492641(opens in a new tab)
Protocol ID:: VICCBRE26029
Primary Investigator:: Vandana Abramson
Phase:: III
Age Group:: Adults
Genders Eligible:: All
Drug:: Abemaciclib, BGB43395, Letrozole (Femara), Palbociclib, Ribociclib
Cancer Type:: Breast Cancers

Overview

The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients with advanced or metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC) who have not received prior systemic treatment for advanced or metastatic disease.

Who Can Participate

Inclusion Criteria

Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the informed consent.

Participants with histologically confirmed locally advanced or metastatic HR+ HER2- breast cancer.

Participants must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.

Adequate organ function.

Exclusion Criteria

Participants who have received prior systemic treatment in the advanced or metastatic setting.

Participants who have received prior treatment with any selective cyclin-dependent kinase 4 (CDK4) or cyclin-dependent kinase 2 (CDK2) targeting agent, or any other investigational anticancer drug in any disease setting, except for prior investigational or approved SERDs in the adjuvant setting, provided that disease recurrence occurred more than 12 months after the last dose of endocrine-based therapy.

Participants with active leptomeningeal disease or uncontrolled, untreated brain metastasis.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Disclaimer

This summary is based on publicly available information from clinicaltrials.gov and is intended to help patients discuss possible trial options with their oncology care team. ClinicalTrials.gov and related public listings do not independently review or approve the safety and scientific merit of every study.

Participation decisions can be made only after review by the study team and your treating clinician.